320 related articles for article (PubMed ID: 29382832)
1. Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor.
Khandelwal A; Kent CN; Balch M; Peng S; Mishra SJ; Deng J; Day VW; Liu W; Subramanian C; Cohen M; Holzbeierlein JM; Matts R; Blagg BSJ
Nat Commun; 2018 Jan; 9(1):425. PubMed ID: 29382832
[TBL] [Abstract][Full Text] [Related]
2. The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with
Mishra SJ; Liu W; Beebe K; Banerjee M; Kent CN; Munthali V; Koren J; Taylor JA; Neckers LM; Holzbeierlein J; Blagg BSJ
J Med Chem; 2021 Feb; 64(3):1545-1557. PubMed ID: 33428418
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Design, Synthesis, and Biological Evaluation of Hsp90β-Selective Inhibitors.
Chaudhury S; Narasimharao Meka P; Banerjee M; Kent CN; Blagg BSJ
Chemistry; 2021 Oct; 27(59):14747-14764. PubMed ID: 34449940
[TBL] [Abstract][Full Text] [Related]
4. Selective Inhibition of the Hsp90α Isoform.
Mishra SJ; Khandelwal A; Banerjee M; Balch M; Peng S; Davis RE; Merfeld T; Munthali V; Deng J; Matts RL; Blagg BSJ
Angew Chem Int Ed Engl; 2021 May; 60(19):10547-10551. PubMed ID: 33621416
[TBL] [Abstract][Full Text] [Related]
5. Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90).
Mak OW; Chand R; Reynisson J; Leung IKH
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31717777
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
Xiao Y; Liu Y
Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
[TBL] [Abstract][Full Text] [Related]
7. Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities.
Dernovšek J; Tomašič T
Pharmacol Ther; 2023 May; 245():108396. PubMed ID: 37001734
[TBL] [Abstract][Full Text] [Related]
8. KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells.
Liu W; Vielhauer GA; Holzbeierlein JM; Zhao H; Ghosh S; Brown D; Lee E; Blagg BS
Mol Pharmacol; 2015 Jul; 88(1):121-30. PubMed ID: 25939977
[TBL] [Abstract][Full Text] [Related]
9. Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.
Prince TL; Kijima T; Tatokoro M; Lee S; Tsutsumi S; Yim K; Rivas C; Alarcon S; Schwartz H; Khamit-Kush K; Scroggins BT; Beebe K; Trepel JB; Neckers L
PLoS One; 2015; 10(10):e0141786. PubMed ID: 26517842
[TBL] [Abstract][Full Text] [Related]
10. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects.
Chan CT; Reeves RE; Geller R; Yaghoubi SS; Hoehne A; Solow-Cordero DE; Chiosis G; Massoud TF; Paulmurugan R; Gambhir SS
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2476-85. PubMed ID: 22895790
[TBL] [Abstract][Full Text] [Related]
11. Gambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90β.
Yim KH; Prince TL; Qu S; Bai F; Jennings PA; Onuchic JN; Theodorakis EA; Neckers L
Proc Natl Acad Sci U S A; 2016 Aug; 113(33):E4801-9. PubMed ID: 27466407
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
[TBL] [Abstract][Full Text] [Related]
13. Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol.
Millson SH; Truman AW; Rácz A; Hu B; Panaretou B; Nuttall J; Mollapour M; Söti C; Piper PW
FEBS J; 2007 Sep; 274(17):4453-63. PubMed ID: 17681020
[TBL] [Abstract][Full Text] [Related]
14. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
15. Cruentaren A binds F1F0 ATP synthase to modulate the Hsp90 protein folding machinery.
Hall JA; Kusuma BR; Brandt GE; Blagg BS
ACS Chem Biol; 2014 Apr; 9(4):976-85. PubMed ID: 24450340
[TBL] [Abstract][Full Text] [Related]
16. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.
Bhatia S; Diedrich D; Frieg B; Ahlert H; Stein S; Bopp B; Lang F; Zang T; Kröger T; Ernst T; Kögler G; Krieg A; Lüdeke S; Kunkel H; Rodrigues Moita AJ; Kassack MU; Marquardt V; Opitz FV; Oldenburg M; Remke M; Babor F; Grez M; Hochhaus A; Borkhardt A; Groth G; Nagel-Steger L; Jose J; Kurz T; Gohlke H; Hansen FK; Hauer J
Blood; 2018 Jul; 132(3):307-320. PubMed ID: 29724897
[TBL] [Abstract][Full Text] [Related]
17. Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.
Mishra SJ; Ghosh S; Stothert AR; Dickey CA; Blagg BS
ACS Chem Biol; 2017 Jan; 12(1):244-253. PubMed ID: 27959508
[TBL] [Abstract][Full Text] [Related]
18. Old and New Approaches to Target the Hsp90 Chaperone.
Sanchez J; Carter TR; Cohen MS; Blagg BSJ
Curr Cancer Drug Targets; 2020; 20(4):253-270. PubMed ID: 31793427
[TBL] [Abstract][Full Text] [Related]
19. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Bickel D; Gohlke H
Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
[TBL] [Abstract][Full Text] [Related]
20. Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.
Casale E; Amboldi N; Brasca MG; Caronni D; Colombo N; Dalvit C; Felder ER; Fogliatto G; Galvani A; Isacchi A; Polucci P; Riceputi L; Sola F; Visco C; Zuccotto F; Casuscelli F
Bioorg Med Chem; 2014 Aug; 22(15):4135-50. PubMed ID: 24980703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
